The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Acrivon Therapeutics Inc shares valued at $617,412 were sold by PERCEPTIVE ADVISORS LLC on Apr 30 ’25. At $1.41 per share, PERCEPTIVE ADVISORS LLC sold 437,881 shares. The insider’s holdings dropped to 3,403,025 shares worth approximately $4.39 million following the completion of this transaction.
Also, PERCEPTIVE ADVISORS LLC sold 298,886 shares, netting a total of over 400,507 in proceeds. Following the sale of shares at $1.34 each, the insider now holds 3,104,139 shares.
Before that, PERCEPTIVE ADVISORS LLC had sold 1,054,669 shares from its account. In a trade valued at $2,056,605, the 10% Owner traded Acrivon Therapeutics Inc shares for $1.95 each. Upon closing the transaction, the insider’s holdings decreased to 1,054,669 shares, worth approximately $5.55 million.
Analysts at KeyBanc Capital Markets started covering the stock with ‘”an Overweight”‘ outlook in a report released in late January. As of September 16, 2024, Ladenburg Thalmann has increased its “Neutral” rating to a “Buy” for ACRV. Earlier on April 29, 2024, Ladenburg Thalmann downgraded its rating. Their new recommendation was “a Neutral” for ACRV stock which previously was a “a Buy”.
Analyzing ACRV Stock Performance
The stock’s lowest price that day was $1.26, but it reached a high of $1.33 in the same session. During the last five days, there has been a drop of approximately -1.53%. Over the course of the year, Acrivon Therapeutics Inc shares have dropped approximately -77.99%. Shares of the company reached a 52-week high of $8.0000 on 02/05/25 and a 52-week low of $1.0500 on 06/02/25.
Support And Resistance Levels for Acrivon Therapeutics Inc (ACRV)
According to the 24-hour chart, there is a support level at 1.2567, which, if violated, would cause prices to drop to 1.2233. In the upper region, resistance lies at 1.3267. The next price resistance is at 1.3633. RSI (Relative Strength Index) is 51.36 on the 14-day chart, showing neutral technical sentiment.
Is Acrivon Therapeutics Inc subject to short interest?
Stocks of Acrivon Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.21 million shares to 1.12 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 1.34 million shares. A decline of -19.04% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.64 of the overall float, the days-to-cover ratio (short ratio) decline to 1.64.
Which companies own the most shares of Acrivon Therapeutics Inc (ACRV)?
In terms of Acrivon Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 1450.39% from the previous closing price of $1.29. Analysts anticipate Acrivon Therapeutics Inc stock to reach 30 by 2025, with the lowest price target being 17. In spite of this, 7 analysts ranked Acrivon Therapeutics Inc stock as Buy at the end of 2025. On March 01, 2024, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $14.
